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Objectives: This preliminary study examined the technical efficacy, safety, and cost of treating arterial occlusions with a
single device that combines pharmacologic and mechanical thrombolysis.
Methods: The technical success, bleeding complications, and costs for the first 26 consecutive patients in whom lower
extremity ischemia was treated with the Trellis infusion catheter (TIC) were analyzed. Procedure time, thrombolytic
infusion time, technical success, bleeding complications (major and intracranial hemorrhage), interventional suite time,
and 30-day amputation-free survival were evaluated.
Results: 15 of 26 patients (58%) who received treatment with the TIC had acute arterial occlusions, and 11 of 26 patients
(42%) had nonacute arterial occlusions. Nineteen of 26 patients (73.1%) received treatment of an infrainguinal occlusion,
and 7 of 26 patients (26.9%) received treatment of a suprainguinal occlusion. Lower extremity native arteries were treated
in 18 of 26 patients (69%), and lower extremity bypass grafts in 8 of 26 patients (31%). The technical success rate with
TIC treatment was 92%, and the 30-day amputation-free survival rate was 96%. There was no difference in technical
success or amputation-free survival rate between acute versus nonacute arterial occlusions, native artery versus bypass
grafts, and suprainguinal versus infrainguinal arterial occlusions. Procedure time was 2.1 0.9 hours, and infusion time
was 0.3  0.2 hours. There were no bleeding complications; however, 3 of 26 patients (11.5%) required further
intervention to treat distal embolization. The overall mean cost for patients with TIC treatment was $3216  $1740.
Conclusions: Early results of TIC treatment in patients with arterial occlusions suggest that it is as effective as traditional
catheter-directed thrombolysis. Furthermore, there were no bleeding complications, likely the result of TIC requiring
shorter procedure and infusion times. (J Vasc Surg 2004;39:556-9.)Three randomized prospective trials have demon-
strated the benefits of catheter-directed thrombolysis
(CDT) to treat acute arterial occlusions.1-3 Despite the
success of this minimally invasive therapy, CDT does have
potential pitfalls, such as risk for intracranial hemorrhage or
major bleeding, distal embolization, recurrent thrombosis,
prolonged infusion time,4 inferior results in chronically
occluded vessels,3 and increased cost.5 In an effort to
improve on these deficiencies, several mechanical or rheo-
lytic thrombectomy devices have been developed.
Although a number of mechanical thrombectomy de-
vices can eliminate some of the deleterious effects of CDT,
such as bleeding complications and prolonged infusion
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doi:10.1016/j.jvs.2003.10.061556time, these devices are also plagued by recurrent thrombo-
sis, distal embolization, and high amputation rates.6,7 The
Trellis infusion catheter (TIC) was designed to improve on
the limitations of both CDT and mechanical thrombec-
tomy devices (Fig 1). The TIC is a hybrid device in that it
combines mechanical and pharmacologic thrombolysis by
isolating the thrombolytic agent between a proximal and
distal occlusion balloon in the thrombosed blood vessel. In
theory, this reduces systemic dispersion of the thrombolytic
agent, therefore limiting exposure and decreasing bleeding
complications by localizing the thrombolytic agent. In
addition, aspiration of the lysed clot at completion poten-
tially removes residual active drug. The occluding balloon
also has the potential advantage of reducing distal emboli-
zation. A battery-powered compliant sinusoidal wire pro-
duces oscillations in the catheter, mechanically mixing the
clot with the lytic agent, as in a blender. This enhances rapid
dissolution of the thrombus by increasing the surface area
of clot exposed to the lytic agent. The dissolved clot is then
aspirated before balloon deflation.
We examined the technical safety, efficacy, and costs of
treating arterial occlusions with the TIC.
METHODS
Between May 2002 and September 2002 data for
the first 26 patients in whom the TIC was used to
treat arterial occlusions of class IIA or IIB limb ischemia
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is a 510(k) Food and Drug Administration–approved de-
vice. All patients gave informed consent for the TIC pro-
cedure and data collection. The study was approved by the
institutional review board at The Cleveland Clinic Founda-
tion and at Stanford University. Clinical case data from 12
institutions (Appendix, online only) were recorded at the
time of the procedure by a manufacturer’s representative,
and entered in a manufacturer-sponsored registry. Results
are reported in accordance with published guidelines from
the Society for Vascular Surgery8,9 and the Society for
Interventional Radiology.10 The data collected for analysis
included procedure time (time in the interventional suite),
infusion time, and 30-day amputation-free survival. Fol-
low-up phone query of each interventionalist was recorded
to document 30-day limb salvage and patency data for all
patients. In addition, we documented whether the treated
vessel had an acute (14 days) or chronic, nonacute arterial
occlusion, whether the vessel treated was a native artery or
bypass graft, and whether the treated vessel was surpaingui-
nal or infrainguinal. All infrainguinal vessels treated were
femoropopliteal bypass grafts constructed with expanded
polytetraethylene. Other procedure details recorded in-
cluded the length of the lesion treated, the specific throm-
bolytic agent and dosage, and the need for adjunctive
interventional or open surgical procedures. Finally, bleed-
ing complications (major and intracranial hemorrhage)
were documented. Technical success was determined at the
time of the procedure by each interventionalist, who mea-
sured and recorded the percentage of thrombus cleared
from the treated vessel. Clinical success was determined by
30-day amputation-free survival.
The average time in the intensive care unit (ICU) for
patients who underwent a single angiography session was
12  6 hours, compared with 24  12 hours for patients
who underwent multiple angiography sessions. These
numbers were applied to TIC treatment for the cost anal-
Fig 1. Trellis infusion catheter. Isolated treatment zone
proximal to the distal balloon.ysis. All TIC-treated patients had one angiography suite
visit.
Therapy specifics were derived from a composition of
products and services. Wholesale acquisition cost for
thrombolytic therapy was extracted from Price-Chek PT
(version 2.16; St Louis, Mo). The cost of the TIC (pro-
vided by Bacchus Vascular, Santa Clara, Calif) was $1495,
and the cost of bleeding was taken from Kalish et al,11 who
reported the excess hospitalization costs of a bleeding event
during systemic thrombolysis for acute myocardial infarc-
tion. The cost of angiography suite time and ICU time
were based on hospital costs from Creighton University
Medical Center adjusted by department-specific and year-
specific ratios.
Statistical comparisons were conducted with the 2
test, Fisher exact test, or Mann-Whitney U test, where
appropriate. All values represent mean  SD.
RESULTS
Demographic data for patients treated with the TIC are
listed in the Table. Specific thrombolytic agents used with
the TIC included Reteplase (7  1.2 units; n  18;
Centocor, Malvern, Pa), Alteplase (5.7  2.6 mg; n  7;
Genentech, South San Francisco, Calif), and Tenecteplase
(3 mg; n  1; Genentech). The average length of occlu-
sions in TIC-treated vessels was 21.5  3.0 cm. The
average TIC procedure time was 2.1  0.9 hours, and the
average TIC infusion time was 0.3  0.2 hours. Fifty-four
percent (14 of 26) of TIC- treated vessels required an
adjunctive interventional procedure (angioplasty with or
without stenting). Fifteen percent (4 of 26) of patients
required an adjunctive open surgical procedure, all of
which were done after thrombolysis with the TIC.
Clinical outcomes are shown in Fig 2 (online only).
Overall technical success was 92%. There was no difference
in technical success for TIC-treated vessels between acute
and nonacute arterial occlusion (91.6% 1.4% vs 92.2%
ween the two balloons, with the clot aspiration port justis bet
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arteries (94.1%  8.9%) than with bypass grafts (86.6% 
16.6%), but this did not reach statistical difference (P 
.15). The technical success rate for suprainguinal and in-
frainguinal occlusions was similar (90.7% 11.7% vs 92.2%
 12.4%; P  .78). Thirty-day amputation-free survival
rate was 96%. For patients with TIC-treated vessels there
were no significant differences in 30-day amputation-free
survival rates between native arteries and bypass grafts
(94.4% vs 100%; P  .69), and no differences between
acute and nonacute arterial occlusion (933.8% vs 100%; P
 .45), and no difference between suprainguinal and in-
frainguinal vessel occlusion (100% vs 94.1%; P  .33).
Finally, there were no episodes of major bleeding compli-
cations or intracranial hemorrhage reported with the TIC.
Three of 26 patients (11.5%) with TIC-treated vessels had
a distal embolic event that required further intervention.
The total cost of the TIC was $3216  $1240. This
included use of the ICU, $600; use of the angiography
suite, $676  $320; thrombolytic agent infused, $445 
$195; TIC, $1495; and bleeding complications, $0. In
addition, cost for critical care stay was $600.
DISCUSSION
Introduction of new medical devices and technologic
advancements mandate continued evaluation of each de-
vice for its safety, clinical benefit, and cost-benefit ratio.12
This study provides preliminary data in reference to the
above for the TIC. We chose a cost-benefit analysis model
to evaluate the data, because it enables evaluation of initial
data.11 Although other models, such as Markov decision
analysis, are useful in determining whether one therapy is
better than another after longer follow-up, this initial anal-
ysis was done to ascertain specifically whether the early
efficacy and costs of such a device warrant continued use
and investigation from a clinical and economic stand-
point.11 Future work with larger numbers of patients and
possibly randomized trials will enable us to determine
whether the long-term results warrant continued use of the
TIC and whether it continues to be as effective as CDT and
open surgical intervention.
One goal of this study was to evaluate the safety and
technical efficacy of the TIC. The technical success rate
(92%) and amputation-free survival rate (97%) indicate that
the device was safe and effective for removing thrombus.
Fig 2 (online only) is an example of the technical success
that can be achieved with the TIC. The mechanical action
of the TIC involves an oscillating catheter inside the blood
vessel that mixes the lytic agent with the clot. With any
Demographic data
No. of
patients Age (y)
Gender (%) Occlusion type
Men Women
Native
artery
By
g
26 70  10 69 31 69intervention involving intraarterial manipulation there is
concern about damaging the blood vessel. Although we did
not evaluate the effects of the TIC on the intima, there was
no reported arterial perforation or dissection secondary to
the device. Significant hemorrhagic complications after use
of other rheolytic thrombectomy devices have been re-
ported, as high as 14%.13 In addition, infusion of a high
dose of lytic agent over a short time may cause concern
about large systemic dispersion of the drug. Though we did
not measure fibrin breakdown products or lytic metabo-
lites, there were no incidents of major or intracranial hem-
orrhage, attesting to the safety and success of isolating the
lytic agent between two occluding balloons and aspirating
the contents at completion. Finally, no patients died, and
the 30-day amputation-free survival of 97% demonstrates
the safety and clinical efficacy of the device. This is signifi-
cantly better than other reports of other mechanical throm-
bectomy devices, in which both amputation and mortality
rates range between 2% and 18%.6
On the other hand, we did find an 11% incidence of
distal embolization. This was higher than expected, and it is
possible this resulted from a too short lytic time or inability
of the catheter to aspirate large fragments of undissolved
thrombus. Since this study was undertaken, the aspiration
mechanism of the device has been changed to enable aspi-
ration of larger clots and eliminate the need to advance a
sheath over the device. Follow-up of these patients is war-
ranted. Distal embolization is a well-known complication
of both CDT and mechanical thrombectomy devices. The
true incidence of peripheral embolization after CDT is
poorly documented; few studies report the incidence and
clinical sequelae. On the other hand, peripheral emboliza-
tion from mechanical thrombectomy devices has been re-
ported in 2% to 18% of cases.6,14 We specifically docu-
mented all embolic events, including embolization to small
collateral vessels. While only two of five instances of embo-
lization required further intervention, it is possible that the
incidence of embolization will decrease with increased fa-
miliarity with the device, refinements in technique, and
device design improvements.
Previous studies have documented the cost-effective-
ness of rheolytic thrombectomy catheters in treatment of
acute coronary syndromes,14 but none has been reported
for the peripheral circulation. The cost analysis from this
study demonstrates that the TIC appears to be more cost-
effective than traditional CDT (unpublished data). Costs
were, on average, $1320 (0.7 times) less with the TIC than
with CDT, despite not taking into account overall hospital
length of stay, open surgical procedures, adjuvant proce-
Presentation (%) Location (%)
Acute Chronic Suprainguinal Infrainguinal
57.7 42.3 26.9 73.1(%)
pass
raft
31
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we could not tabulate in this study), and comparison of the
TIC with the least expensive drug. It is possible that the
difference in costs may have been significantly greater were
these taken into account. Mechanical thrombectomy de-
vices were developed to minimize the risks of open surgical
procedures and CDT, inasmuch as mortality from acute
limb ischemia remains high.15 CDT is less invasive and less
physiologically stressful than open surgical revasculariza-
tion. However, its utility has been questioned because of its
high costs.5 Similar to CDT, the TIC itself appears expen-
sive, but this report demonstrates that it may save money
because of decreased angiography suite time from not
having multiple sessions, ICU monitoring postoperatively,
quantity of thrombolytic agents needed, and bleeding
complications. Clinical and economic comparisons with
other rheolytic thrombectomy catheters is warranted.
Despite satisfactory results reported here for both costs
and technical efficacy, this study has inherent drawbacks
and is not without pitfalls. It is a retrospective evaluation of
data and not a randomized trial, only early results are
reported, and data from one center were extrapolated for
costs. In addition, on average two patients were treated per
center, which likely produces a selection biases. However,
the procedure times in the angiogram suite derived from
Creighton University Medical Center data were close to the
angiography suite time and ICU length of stay reported by
Korn et al.5 Moreover, ICU estimated costs of $1200 per
day and general medical ward costs of $600 per day are
similar to those reported by Bosch et al,16 and the angiog-
raphy suite costs in our model for CDT are similar to those
of other studies reported in the literature.17,18
The Surgery vs Thrombolysis for Ischemic Lower Ex-
tremity trial demonstrated that traditional CDT is less
effective for chronic lower extremity ischemia. Although
the TIC was equally effective for both acute and nonacute
lesions, the numbers presented in this report are too small
to enable us to draw meaningful conclusions regarding its
success in treating chronically occluded blood vessels. Also,
it is possible that the nonacute occluded vessels treated with
the TIC were subacute (14-30 days) or vessels that may
have been easily recanalized without use of the TIC. In
addition, there is likely a selection bypass in treating non-
acute vessels, inasmuch as the lesions treated in this study
were those that had a high chance of success with TIC
treatment. Furthermore, the size of vessel treated and
degree of ischemia in chronically occluded small vessels
make comparisons of CDT with the TIC invalid. However,
the novel aspects of the TIC that make it attractive for both
acute and nonacute lower extremity ischemia in medium to
large vessels is that it combines two forms of therapy that
aim to lower complication rates such as bleeding and distal
embolization. In the former it held true, in that bleeding
complications were nil with the TIC, but distal emboliza-
tion remains a concern.REFERENCES
1. Ouriel K, Veith FJ, Sasahara AA. A comparison of recombinant uroki-
nase with vascular surgery as initial treatment for acute arterial occlusion
of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS)
Investigators. N Engl J Med 1998;338:1105-11.
2. Ouriel K, Shortell CK, DeWeese JA, Green RM, Francis CW, Azodo
MV, et al. A comparison of thrombolytic therapy with operative revas-
cularization in the treatment of acute peripheral arterial ischemia. J Vasc
Surg 1994;19:1021-30.
3. STILE Investigators. Results of a prospective randomized trial evaluat-
ing surgery versus thrombolysis for ischemia of the lower extremity: The
STILE trial. Ann Surg 1994;220:251-68.
4. Ouriel K, Gray B, Clair DG, Olin J. Complications associated with the
use of urokinase and recombinant tissue plasminogen activator for
catheter directed peripheral arterial and venous thrombolysis. J Vasc
Interv Radiol 2000;11:295-8.
5. Korn P, Khilnani NM, Fellers JC, Lee TY, Winchester PA, Bush HL, et
al. Thrombolysis for native arterial occlusions of the lower extremities:
clinical outcome and cost. J Vasc Surg 2001;33:114-57.
6. Kasirajan K, Marek JM, Langsfeld M. Mechanical thrombectomy as a
first-line treatment for arterial occlusion. Semin Vasc Surg 2001;14:
123-31.
7. Kasirajan K, Gray B, Beavers F, Clair DG, Greenberg R, Mascha E, et al.
Rheolytic thrombectomy in the management of acute and subacute
limb-threatening ischemia. J Vasc Interv Radiol 2001;12:413-21.
8. Ahn SS, Rutherford RB, Becker GJ, Comerota AJ, Johnston KW,
McClean GK, et al. Reporting standards for lower extremity arterial
endovascular procedures. J Vasc Surg 1993;17:1103-7.
9. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et
al. Recommended standards for reports dealing with lower extremity
ischemia: revised version. J Vasc Surg 1997;26:517-38.
10. Patel N, Sacks D, Patel RI, Moresco KP, Ouriel K, Gray R, et al. SCIVR
reporting standards for the treatment of acute limb ischemia with the
use of transluminal removal of arterial thrombus. J Vasc Interv Radiol
2001;12:559-70.
11. Kalish SC, Gurwitz JH, Krumholz HM, Avorn J. A cost-effectiveness
model of thrombolytic therapy for acute myocardial infarction. J Gen
Intern Med 1995;10:321-30.
12. Abel DB. Ongoing FDA evaluation of approved endografts. J Vasc Surg
2003;37:902-3.
13. Kasirajan K, Haskal Z, Ouriel K. The use of mechanical thrombectomy
devices in the management of acute peripheral arterial occlusive disease.
J Vasc Interv Radiol 2001;12:405-11.
14. Cohen DJ, Ramee S, Baim DS, Sharma S, Carrozza JP, Cosgrove R, et
al. Economic assessment of rheolytic thrombectomy versus intracoro-
nary urokinase for treatment of extensive intracoronary thrombus:
results from a randomized clinical trial. Am Heart J 2001;142:648-56.
15. Hoch JR, Tullis MJ, Acher CW, Heisy DM, Crummy AB, McDermott
JC, et al. Thrombolysis vs surgery as the initial management for native
artery occlusion: efficacy, safety, and cost. Surgery 1994;116:649-57.
16. Bosch JL, Haaring C, Meyerovitz MF, Cullen KA, Hunink MGM.
Cost-effectiveness of percutaneous treatment of iliac artery occlusive
disease in the United States. AJR 2000;175:517-21.
17. Bosch JL, Tetteroo E, Mali W, Hunink MGM. Iliac arterial occlusive
disease: cost effectiveness analysis of stent placement versus percutane-
ous transluminal angioplasty. Radiology 1998;208:641-8.
18. Hoch JR, Tullis MJ, Acher CW, Heisy DM, Crummy AB, McDermott
JC, et al. Thrombolysis vs surgery as the initial management for native
artery occlusion: efficacy, safety, and cost. Surgery 1994;116:649-57.
Submitted Jun 12, 2003; accepted Oct 14, 2003.
Additional material for this article may be found online
at www.mosby.com/jvs.
